Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. - Wikidata - wikimedia - TriplyDB

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

http://www.wikidata.org/entity/Q34781067

about

Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways Using large-scale molecular data sets to improve breast cancer treatment.Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes Comparison of cantharidin toxicity in breast cancer cells to two common chemotherapeutics Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α Targeted therapies for breast cancer.Optimal structural inference of signaling pathways from unordered and overlapping gene sets.A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.Toward individualized breast cancer therapy: translating biological concepts to the bedside.HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies The molecular profile of luminal B breast cancer BOLERO-2 - will this change practice in advanced breast cancer?Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer.Targeted therapies in breast cancer: are heart and vessels also being targeted?Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.Integration of endocrine therapy with targeted agents.Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.Alopecia with endocrine therapies in patients with cancer.

P2860

Q26741153-DAAB4448-CD69-4922-8DBA-5E64B3B98A22 Q26995549-CBF20802-58A1-4600-ACCB-AF6125B6363E Q27001260-1EEE6189-DCB4-4221-AC5A-2C614D764A69 Q28082793-2918DACF-2262-4CA4-85D8-29552E99CE4B Q28084585-4F78B71D-6DAC-4643-A222-9DB9FE4E027B Q30656126-5FD5FE39-73AF-4E05-9BEF-B0458E7D58D8 Q33648503-E9406CA3-4A65-433C-8C9D-B56A7D260503 Q33656801-0B9D1080-FA3D-4FE5-8F6C-FBB7BD1AA350 Q33691211-FAA7B76A-7565-4C9C-9811-A46232E99177 Q34267632-9854143D-D00E-407D-860A-D322F4F983A1 Q34296534-08345A1B-D894-42D7-8381-8DCB64C097CF Q34657786-E58B7D20-5027-4C6F-8CA9-5F4A4FCBED32 Q34793260-F894AC2B-E556-43E1-B74F-42BF88886CD3 Q34852154-3D234C7B-9B77-4F9C-A7C0-8F53962FDB3C Q34855692-8D4958D1-89AA-4702-8944-03B2D1C21B3E Q35034708-4FBC169C-ACF7-4FDC-A4CA-4589C8E5A335 Q35040890-72EC63EB-E2AC-41A5-9550-D141FFC17824 Q35180278-DA6A627F-D477-4264-BD51-7C59F2672A33 Q35372584-3F2C2987-1854-442B-84ED-9CDA1D082E28 Q35754761-241C5554-D5F9-4C5E-A8EF-B86832415AD3 Q35771300-B71C3BF0-0DB9-4B19-999F-17BCA22C1471 Q35913199-79474648-8948-4C1A-BA62-6528B1DE7B87 Q36029524-A2D908AB-9544-441D-9B60-C3617A764E72 Q36059078-B069E9DA-4E65-4251-A108-CF7C469C615F Q36127379-EB35FED6-218E-4D17-97E7-B1261AC410FE Q36196676-98FA4CC7-517C-4C80-9587-90D18D104E82 Q36245315-D45BEBFE-11DE-448D-B12A-D4D1E492A36B Q36245320-FAD07976-B2F0-41D8-A512-5AB1248C79A1 Q36245324-4D01751A-6BA3-4375-97F4-8BA055433A3D Q36245528-DA38425C-BC7E-40F0-8800-D1379C0D1F43 Q36250585-AAFAB8A7-9761-4094-824E-9969EFED0033 Q36480044-4F9EEBA5-CADD-473E-8DA5-4CB538445C07 Q36517144-3A7CF91A-6282-47B6-8C82-F1F2FABE82B3 Q36547566-3B59D27F-5029-49D2-A66E-F6F9CE03AA2D Q36568571-EFC5005C-A96F-4469-A571-CD2E4B028142 Q36902056-5D66D123-4405-4388-9F21-A2B2ED14D627 Q37013935-1B0DAC04-DC1F-48A8-85FF-7139428BC153 Q37039801-FC5E0452-915E-4545-B6F1-015EC533B3D6 Q37217695-84A0B2CA-2710-4E0E-BB49-DE5B69A2A860 Q37247197-258B3873-F5FA-4CFC-85F8-B82AE57CFCCD

P2860

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

http://www.wikidata.org/entity/Q34781067

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Gefitinib or placebo in combin ...... : a randomized phase II study.

@ast

Gefitinib or placebo in combin ...... : a randomized phase II study.

@en

Gefitinib or placebo in combin ...... : a randomized phase II study.

@nl

type

label

Gefitinib or placebo in combin ...... : a randomized phase II study.

@ast

Gefitinib or placebo in combin ...... : a randomized phase II study.

@en

Gefitinib or placebo in combin ...... : a randomized phase II study.

@nl

prefLabel

Gefitinib or placebo in combin ...... : a randomized phase II study.

@ast

Gefitinib or placebo in combin ...... : a randomized phase II study.

@en

Gefitinib or placebo in combin ...... : a randomized phase II study.

@nl

P1433

Q34781067-F4F1B665-2A72-446D-BA5D-EE1C5704772D

P1476

Q34781067-355005D4-8F28-491A-88A6-694F5858CBCB

P2093

Q34781067-0562861D-BA8F-4257-94A4-1FD89217AED9

Q34781067-303E8D95-A40A-4B24-8FDD-D36D7521B47A

Q34781067-40F9EC45-563F-4082-97F9-901D45BA0D87

Q34781067-637A08D7-265F-4334-9334-F9F546B8327B

Q34781067-7569B51F-A830-4C14-8401-1CA0F430B517

Q34781067-82D11E9A-401C-4F8B-B78B-1F720CB5B995

Q34781067-8C3F4B73-AE71-4FBC-B5FD-09B1FA289971

Q34781067-B805499D-6BE2-461E-A64A-17F8903124CE

Q34781067-BC6BB76D-BF96-4C96-8DFA-A40A6956FDA4

Q34781067-DBB10E08-9774-44AA-8E75-6B1090F7634D

P2860

Q34781067-02ABAAE8-EE39-4E50-BBF0-A0A09CF75CBE

Q34781067-05C6A561-E46F-42EF-A5F2-52CC41B66C48

Q34781067-05F8DEE2-239E-46A6-B404-9D4493D7CD61

Q34781067-12F10FEB-E35A-41D9-88E3-6D0E96A77B44

Q34781067-13D2A4C3-BCA8-4D0A-BB62-80ECE341F8DA

Q34781067-2BB02D96-D44E-4A36-B1EA-7F2360400B24

Q34781067-2C3D8223-F614-48A5-9B9A-94765B44DB2C

Q34781067-2F0F1436-401D-4CE0-A36A-7A3EA2C844B8

Q34781067-3606D625-0497-4DB1-9CC2-FB201DF95B68

Q34781067-54C54187-93FE-4094-B385-68872F030D8A

P304

Q34781067-8E4D3E76-3B84-4273-9D85-D7DFA1576A57

P31

Q34781067-CB5EEE06-3F2C-41A6-89E5-B28E5568B313

P356

Q34781067-BA25C2B8-4BBC-4E0F-815E-C6DE9620933B

P407

Q34781067-E565D274-F200-411B-A368-D75E45CAF582

P433

Q34781067-15FACF5D-8776-43DE-8F3D-6C1F8604CE30

P478

Q34781067-9A96EDAF-DC84-4227-AAC8-963FB4C5F22B

P577

Q34781067-FC84DDE5-E9CC-4733-8730-26A72B918F5E

P5875

Q34781067-282ECC68-A187-44C6-BFFF-184F1EB73C1E

P698

Q34781067-BCA09C26-9CFB-4B64-8267-08FB66AECD7C

P921

Q34781067-B74C53A6-4021-416D-B9D1-67CB8FB6AE67

P932

Q34781067-B3AB318E-D929-403E-BDEF-CADA5A3DA87E

P356

1078-0432.CCR-10-1869

P1433

Clinical Cancer Research

P1476

Gefitinib or placebo in combin ...... : a randomized phase II study.

@en

P2093

C Kent Osborne

http://www.w3.org/2001/XMLSchema#string

Carolina Gutierrez

http://www.w3.org/2001/XMLSchema#string

Craig Underhill

http://www.w3.org/2001/XMLSchema#string

David L Rimm

http://www.w3.org/2001/XMLSchema#string

Ilenia Migliaccio

http://www.w3.org/2001/XMLSchema#string

Jean Robert

http://www.w3.org/2001/XMLSchema#string

John R Mackey

http://www.w3.org/2001/XMLSchema#string

Luc Y Dirix

http://www.w3.org/2001/XMLSchema#string

Mark Sellers

http://www.w3.org/2001/XMLSchema#string

Patrick Magill

http://www.w3.org/2001/XMLSchema#string

P2860

HER-2 gene amplification can be acquired as breast cancer progresses

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

A flexible design for multiple armed screening trials.

Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

Multiple estrogen receptor assays in human breast cancer.

P304

1147-1159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-1869

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49742075

http://www.w3.org/2001/XMLSchema#string

P698

21220480

http://www.w3.org/2001/XMLSchema#string

P921

P932

3074404

http://www.w3.org/2001/XMLSchema#string